Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity.
Chuan QinMin ZhangDa-Peng MouLuo-Qi ZhouMing-Hao DongLiang HuangWen WangSong-Bai CaiYun-Fan YouKe ShangJun XiaoDi WangChun-Rui LiYi HaoMichael HemingLong Jun WuGerd Meyer Zu HörsteChen DongBi-Tao BuDai-Shi TianWei WangPublished in: Science immunology (2024)
Chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of neurological autoimmune diseases is promising, but CAR T cell kinetics and immune alterations after treatment are poorly understood. Here, we performed single-cell multi-omics sequencing of paired cerebrospinal fluid (CSF) and blood samples from patients with neuromyelitis optica spectrum disorder (NMOSD) treated with anti-B cell maturation antigen (BCMA) CAR T cells. Proliferating cytotoxic-like CD8 + CAR T cell clones were identified as the main effectors in autoimmunity. Anti-BCMA CAR T cells with enhanced features of chemotaxis efficiently crossed the blood-CSF barrier, eliminated plasmablasts and plasma cells in the CSF, and suppressed neuroinflammation. The CD44-expressing early memory phenotype in infusion products was potentially associated with CAR T cell persistence in autoimmunity. Moreover, CAR T cells from patients with NMOSD displayed distinctive features of suppressed cytotoxicity compared with those from hematological malignancies. Thus, we provide mechanistic insights into CAR T cell function in patients with neurological autoimmune disease.
Keyphrases
- single cell
- cerebrospinal fluid
- cell therapy
- rna seq
- spectrum disorder
- high throughput
- induced apoptosis
- multiple sclerosis
- traumatic brain injury
- stem cells
- mesenchymal stem cells
- low dose
- brain injury
- celiac disease
- cerebral ischemia
- working memory
- signaling pathway
- combination therapy
- inflammatory response
- aqueous solution